Merck's WINREVAIR™ Gains EU Approval for PAH Treatment

Aug 26, 2024, 06:41 AM

Merck has received approval from the European Commission for WINREVAIR™ (sotatercept) in combination with other therapies for the treatment of pulmonary arterial hypertension (PAH) in adult patients with functional class II-III. This approval marks a significant advancement in the treatment options available for PAH, a condition characterized by high blood pressure in the arteries of the lungs, which can lead to heart failure if untreated. The approval of WINREVAIR™ is expected to enhance the therapeutic landscape for PAH patients in Europe.